Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
3.172
+0.032 (1.02%)
Jan 21, 2025, 4:00 PM EST - Market closed
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 29 employees as of December 31, 2023. The number of employees increased by 8 or 38.10% compared to the previous year.
Employees
29
Change (1Y)
8
Growth (1Y)
38.10%
Revenue / Employee
n/a
Profits / Employee
-$973,123
Market Cap
113.99M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | 8 | 38.10% |
Dec 31, 2022 | 21 | 0 | - |
Dec 31, 2021 | 21 | 9 | 75.00% |
Dec 31, 2019 | 12 | 0 | - |
Dec 31, 2018 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
EPRX News
- 2 months ago - Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - PRNewsWire
- 3 months ago - Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - PRNewsWire
- 3 months ago - Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis - PRNewsWire